Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs Velvet Rx

GoodRx
Graded #116

Higher grade

vs+11.499999999999993
Velvet Rx
Graded #381

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 58.1/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +38
80
42
Dose & formulationVelvet Rx +5
70
75
Clinical oversightGoodRx +2
69
67
Labs & monitoringVelvet Rx +2
51
53
FulfillmentGoodRx +24
81
57
Contract termsEven
55
55
GoodRx · left barVelvet Rx · right bar

The numbers

MetricGoodRxVelvet Rx
WeighScore69.6/10058.1/100
GradeCC
Scorecard rank#116#381
SemaglutideNot disclosed$299/mo (compounded)
Tirzepatide$299/mo (brand Zepbound)$359/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
Velvet Rx

Graded #381 · C

Strengths

  • Public pricing across 3 SKUs (semaglutide $299, tirzepatide $359, oral GLP-1 $349) — uncommon in compounded telehealth
  • First-month promo pricing shown upfront ($139 sema / $199 tirz / $189 oral)
  • Single monthly price includes consult, prescription, 4 weeks of medication, and free 1–2 day shipping
  • FSA/HSA eligible
  • Three options under one roof: injectable sema, injectable tirz, and an oral GLP-1

Where it loses points

  • Oral GLP-1 SKU doesn't name the specific drug — a real gap given Rybelsus, Foundayo, and compounded oral semaglutide differ clinically
  • No LegitScript or NABP .pharmacy seal displayed
  • No legal entity name disclosed
  • No physical address disclosed
  • Compounding pharmacy partner not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard